Marenzi Giancarlo, Lauri Gianfranco, Assanelli Emilio, Campodonico Jeness, De Metrio Monica, Marana Ivana, Grazi Marco, Veglia Fabrizio, Bartorelli Antonio L
Centro Cardiologico Monzino, I.R.C.C.S., Institute of Cardiology of the University of Milan, Milan, Italy.
J Am Coll Cardiol. 2004 Nov 2;44(9):1780-5. doi: 10.1016/j.jacc.2004.07.043.
The aim of this research was to assess the incidence, clinical predictors, and outcome of contrast-induced nephropathy (CIN) after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
Contrast-induced nephropathy is associated with significant morbidity and mortality after PCI. Patients undergoing primary PCI may be at higher risk of CIN because of hemodynamic instability and unfeasibility of adequate prophylaxis.
In 208 consecutive AMI patients undergoing primary PCI, we measured serum creatinine concentration (Cr) at baseline and each day for the following three days. Contrast-induced nephropathy was defined as a rise in Cr >0.5 mg/dl.
Overall, CIN occurred in 40 (19%) patients. Of the 160 patients with baseline Cr clearance >/=60 ml/min, only 21 (13%) developed CIN, whereas it occurred in 19 (40%) of those with Cr clearance <60 ml/min (p < 0.0001). In multivariate analysis, age >75 years (odds ratio [OR] 5.28, 95% confidence interval [CI] 1.98 to 14.05; p = 0.0009), anterior infarction (OR 2.17, 95% CI 0.88 to 5.34; p = 0.09), time-to-reperfusion >6 h (OR 2.51, 95% CI 1.01 to 6.16; p = 0.04), contrast agent volume >300 ml (OR 2.80, 95% CI 1.17 to 6.68; p = 0.02) and use of intraaortic balloon (OR 15.51, 95% CI 4.65 to 51.64; p < 0.0001) were independent correlates of CIN. Patients developing CIN had longer hospital stay (13 +/- 7 days vs. 8 +/- 3 days; p < 0.001), more complicated clinical course, and significantly higher mortality rate (31% vs. 0.6%; p < 0.001).
Contrast-induced nephropathy frequently complicates primary PCI, even in patients with normal renal function. It is associated with higher in-hospital complication rate and mortality. Thus, preventive strategies are needed, particularly in high-risk patients.
本研究旨在评估急性心肌梗死(AMI)患者接受直接经皮冠状动脉介入治疗(PCI)后对比剂肾病(CIN)的发生率、临床预测因素及预后。
PCI术后对比剂肾病与显著的发病率和死亡率相关。接受直接PCI的患者因血流动力学不稳定及充分预防措施不可行,可能发生CIN的风险更高。
在208例连续接受直接PCI的AMI患者中,我们于基线时及随后三天每天测量血清肌酐浓度(Cr)。对比剂肾病定义为Cr升高>0.5mg/dl。
总体而言,40例(19%)患者发生CIN。在160例基线Cr清除率≥60ml/min的患者中,仅21例(13%)发生CIN,而Cr清除率<60ml/min的患者中有19例(40%)发生CIN(p<0.0001)。多因素分析显示,年龄>75岁(比值比[OR]5.28,95%置信区间[CI]1.98至14.05;p=0.0009)、前壁梗死(OR 2.17,95%CI 0.88至5.34;p=0.09)、再灌注时间>6小时(OR 2.51,95%CI 1.01至6.16;p=0.04)、对比剂用量>300ml(OR 2.80,95%CI 1.17至6.68;p=0.02)及使用主动脉内球囊(OR 15.51,95%CI 4.65至51.64;p<0.0001)是CIN的独立相关因素。发生CIN的患者住院时间更长(13±7天对8±3天;p<0.001),临床过程更复杂,死亡率显著更高(31%对0.6%;p<0.001)。
对比剂肾病常使直接PCI复杂化,即使在肾功能正常的患者中也是如此。它与更高的院内并发症发生率和死亡率相关。因此,需要采取预防策略,尤其是在高危患者中。